Brief: DSM H1 Adjusted EBITDA For Continuing Operations Up At 746 Million Euros

Koninklijke DSM NV

02/08/2022 06:07

Aug 2 (Reuters) - Koninklijke DSM NV  DSMN.AS :
    * DSM REPORTS H1 2022 RESULTS
    * H1 ADJUSTED NET PROFIT WAS UP 14% TO EUR 335M
    * INTERIM DIVIDEND OF EUR 0.93 PER ORDINARY SHARE
    * DSM WILL ONLY PROVIDE AN OUTLOOK FOR ITS CONTINUING
OPERATIONS
(HEALTH, NUTRITION & BIOSCIENCE, AND CORPORATE ACTIVITIES)
    * THE OUTLOOK FOR THESE CONTINUING ACTIVITIES IS UNCHANGED:
DSM
EXPECTS TO DELIVER A HIGH-SINGLE DIGIT ADJUSTED EBITDA INCREASE
    * H1 SALES FOR CONTINUING OPERATIONS EUR 4.12 BILLION VERSUS
EUR
3.52 BILLION YEAR AGO
    * FOLLOWING ANNOUNCEMENTS IN APRIL AND MAY 2022 OF THE
INTENDED
SALE OF DSM'S TWO REMAINING MATERIALS BUSINESSES, THESE ARE NOW
REPORTED AS ASSETS HELD FOR SALE AND AS DISCONTINUED OPERATIONS
    * H1 ADJUSTED EBITDA FOR CONTINUING OPERATIONS EUR 746
MILLION
VERSUS EUR 693 MILLION YEAR AGO
    * H1 ADJUSTED EBITDA FOR CONTINUING OPERATIONS EUR POSITIVE
PRICING MOMENTUM AND FAVORABLE FOREIGN EXCHANGE EFFECTS
SUPPORTING OUR FULL YEAR OUTLOOK MILLION VERSUS EUR 925 MILLION
YEAR AGO

Source text for Eikon:  urn:newsml:reuters.com:*:nPrepHNtBa
Further company coverage:  DSMN.AS 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))